LBCTR2020071296尚未招募2 期
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Patients with Non-Transfusion Dependent ß-Thalassemia Intermedia
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 至 65（—）
- 性别
- All
入选标准
- •1. Patient must have given written informed consent and be able to comply with all study requirements
- •2. Aged 18-65 years old, inclusive, at the time of informed consent
- •3. Clinical diagnosis of ß-Thalassemia Intermedia with genotypic confirmation of ß-globin gene mutations including but not limited to Hemoglobin E
- •(HbE)/ß-thalassemia
- •4. Patient must be non-transfusion dependent as defined by: No more than 6 transfusions in the past 12-month period, and no transfusions in the
- •8-week period prior to Day 1
- •5. Mean Hb within the range 6.0-10.0 g/dL, inclusive, with this mean based on all Hb measurements taken in the Screening Period that are at least
- •6 weeks after the most recent transfusion for that patient. This mean must be based on at least 2 Hb measurements
- •6. LIC within the range of 3.0-20.0 mg Fe/g dry weight, inclusive
- •7. Chelators will be permitted provided the patient has been on a stable dose for at least 3 months prior to Day 1, with LIC > 5.0 mg Fe/g dry weight
- •and serum ferritin > 300 ng/mL
- •8.Females must be non-pregnant and non-lactating, and one of the following: (i) surgically sterile (e.g., tubal occlusion, hysterectomy,
- •bilateral salpingectomy, bilateral oophorectomy), (ii) postmenopausal (defined as 12 months of spontaneous amenorrhea without an alternative
- •medical cause and follicle stimulating hormone [FSH] levels in the postmenopausal range for the laboratory involved), (iii) abstinent, or (iv)
- •if engaged in sexual relations of child-bearing potential, the patient must be using a highly effective contraceptive method from the
- •time of signing the informed consent form until at least 13 weeks after the last dose of ISIS 702843 Males must be one of the following: (i) surgically
- •sterile, (ii) abstinent, or (iii) if engaged in sexual relations with a female of child-bearing potential, the patient must be using a highly effective
- •contraceptive method from the time of signing the informed consent form until at least 13 weeks after the last dose of ISIS 702843.
排除标准
- •1. Genotypic confirmation of either a-globin gene triplication or sickle hemoglobin (HbS)/ß-thalassemia, as determined by genetic assessment of
- •blood-related disorders
- •2. Clinically significant abnormalities in medical history or physical examination, which at the discretion of the PI will pose significant additional risk to
- •the patient in participating in the study
- •3. Clinically significant abnormalities in Screening laboratory values that would render a patient unsuitable for inclusion, at the discretion of the PI
- •4. Current use of iron-chelation therapy if LIC is 3.0–5.0 mg Fe/g dry weight, inclusive, or if serum ferritin = 300 ng/mL
- •5. Symptomatic splenomegaly, including abdominal pain or organ obstruction, or evidence of hypersplenism, such as low white blood cell (WBC)
- •count and/or low platelets
- •6. Platelet count < LLN, or platelet count > 1,000 x 109/L
- •7. Significant concurrent/recent coagulopathy; history of non-traumatic significant bleeding; history of immune thrombocytopenic purpura (ITP);
- •current use of SC anti-coagulants; history of thrombotic events, including stroke or deep vein thrombosis (DVT)
- •8. Clinically significant renal dysfunction which at the discretion of the PI will pose significant additional risk to the patient in participating in the study
- •9. Estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m2, using CKD-EPI
- •10. Clinically significant liver function test (LFT) abnormalities
- •11. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)> 3.0 × ULN
- •12. Historical diagnosis of cirrhosis, or current signs and symptoms of cirrhosis
- •13. Fasting blood glucose > 2.0 × ULN
- •14. Significant pulmonary hypertension (PHT) defined as tricuspid regurgitation > 3.0 meters per second (m/s) on echocardiography and/or requiring
- •15. Uncontrolled hypertension (which for this protocol is considered > 140 mm Hg systolic or > 90 mm Hg diastolic)
- •16. Heart failure class 3 or higher (New York Heart Association, NYHA)
- •17. Ejection fraction < 50% by echocardiogram, multigated acquisition (MUGA), or cardiac magnetic resonance imaging (MRI)
- •18. Patients unable to have MRI performed, for example, because of a pacemaker or implantable cardioverter-defibrillator (MRI is being used to
- •measure LIC)
- •19. Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Day 1
- •20. Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C (unless treatment has caused the patient to test negative
- •for hepatitis C), or chronic hepatitis B
- •21. Unwillingness to comply with study procedures, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the
- •Investigator
- •22. Recent introduction of hydroxyurea (within 6 months prior to Day 1)
- •23. Treatment with or exposure to another investigational drug, biological agent, ASO, small interfering ribonucleic acid (siRNA), or device within
- •one month of Screening, or 5 half-lives of investigational agent, whichever is longer; or:
- •-Treatment with or exposure to sotatercept (ACE-011), luspatercept (ACE-536), or ruxolitinib within 4 months of Screening
- •-Treatment with or exposure to hematopoietic stimulating agents (e.g., EPOs) or any hypoxia-inducible factor prolyl hydroxylase inhibitors
- •-Prior bone marrow transplant, stem cell transplant, or gene therapy
- •24. Regular use of alcohol w
研究者
相似试验
进行中（未招募）
1 期
A study to look at how effective, how safe and how well tolerated a study drug called ISIS 702843 is when given under the skin to patients with Non-Transfusion Dependent ß-Thalassemia Intermedia. This study will also look at the movement of ISIS 702843 in the body and how ISIS 702843 affects the body.EUCTR2019-003505-96-GRIonis Pharmaceuticals, Inc.29
进行中（未招募）
1 期
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of sapablursen (ISIS 702843-CS4) Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)Polycythemia VeraCTIS2024-512482-14-00Ionis Pharmaceuticals Inc.60
进行中（未招募）
1 期
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)MedDRA version: 21.1Level: LLTClassification code 10036061Term: Polycythemia veraSystem Organ Class: 100000004864Polycythemia VeraEUCTR2021-003704-40-HUIonis Pharmaceuticals, Inc.48
招募中
2 期
A Phase 2, Randomized, Open-Label Study to Evaluate theSafety and Efficacy of GS-4774 for the Treatment ofVirally-Suppressed Subjects with Chronic Hepatitis BACTRN12613001080718Gilead Sciences, Inc175
进行中（未招募）
1 期
A Phase 2, Randomized, Open-Label Study to Evaluate ECG Results and Pharmacokinetic Parameters for Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Combination with Lumiliximab Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia.Previously Untreated Chronic Lymphocytic Leukemia (CLL)MedDRA version: 9.1Level: LLTClassification code 10008958Term: Chronic lymphocytic leukaemiaEUCTR2008-002204-25-FRBiogen Idec Ltd60